Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant

发现 3-[2-(咪唑并[1,2-b]哒嗪-3-基)乙炔基]-4-甲基-N-{4-[(4-甲基哌嗪-1-基)甲基]-3-(三氟甲基)苯基}苯甲酰胺 (AP24534)，一种强效、口服活性的断点簇区域-abelson (BCR-ABL) 激酶泛抑制剂，包括 T315I 守门人突变体